ZEISS CLINIC 360 receives FDA 510k clearance

Carl Zeiss Meditec AG has secured FDA 510(k) clearance for ZEISS CLINIC 360, an all-in-one cloud and browser-based software platform designed to consolidate ophthalmic diagnostic and medical record data into a single, unified patient view. The company noted it expects commercial availability in the United States in early fall 2026.¹

CLINIC 360 is built to pull DICOM-enabled data from ZEISS's own diagnostic device lines, including the CIRRUS optical coherence tomography (OCT) platform, the CLARUS widefield retinal imaging system, and the Humphrey Field Analyzer (HFA), alongside data from compatible third-party devices. The platform also integrates with practices' electronic medical records, pulling in risk factors, family history, and other patient background typically scattered across separate systems. Rather than requiring locally installed software, CLINIC 360 runs through a cloud-based web browser.

Federico Villegas, head of ZEISS Medical Technology US, said the platform “reflects our commitment to reducing complexity across the care journey and helping practitioners work more efficiently while maintaining focus on their patients.”¹ Anuj Kalra, head of chronic disease management at the company, characterized the software as representing “a new standard in patient care support, helping clinicians identify meaningful change more quickly.”¹

Clinical rationale: Disease summaries and progression alerts

The core clinical pitch behind CLINIC 360 is consolidation. Ophthalmologists managing chronic, progressive conditions such as glaucoma routinely draw on visual field tests, OCT scans, fundus photography, intraocular pressure readings, and medication history, data that frequently lives in separate device-specific viewers and EMR modules rather than a single interface. CLINIC 360's disease-based summaries are designed to compile that information into interactive views built around a specific condition, with color-coded alerts and trend analysis intended to flag glaucoma progression more quickly than manual chart review would allow. The platform also includes secure case-sharing functionality, letting clinicians route a patient's consolidated record to a colleague for collaborative review.

That design responds to a documentation problem eye care has wrestled with for years. The American Academy of Ophthalmology has published practice guidance specifically addressing the difficulty of integrating diagnostic device output into EHR workflows², noting that device data and chart data often remain functionally separate even after nominal integration, forcing clinicians to toggle between systems during a visit.

Why glaucoma monitoring is the proving ground

ZEISS's emphasis on chronic disease management, and glaucoma in particular, tracks with the scale of the underlying patient population. A 2022 prevalence analysis published in JAMA Ophthalmology³ estimated that 4.22 million US adults had glaucoma, with roughly 1.49 million experiencing vision-affecting disease, figures notably higher than earlier estimates that were limited to adults over 40. BrightFocus Foundation's National Glaucoma Research program⁴ puts current global prevalence at approximately 80 million people, a number projected to exceed 111 million by 2040.

Context within ZEISS's broader portfolio strategy

CLINIC 360 extends a pattern Ophthalmology Times has tracked in ZEISS's recent US announcements⁵, which have increasingly paired hardware releases with software and data initiatives. These have been aimed at the same installed base of CIRRUS, CLARUS, and HFA users, which is part of a wider industry move to treat diagnostic devices as data sources for connected platforms rather than standalone instruments. Other manufacturers have pursued a similar interoperability push this year: Heidelberg Engineering's recent FDA clearance for its updated SPECTRALIS software⁶ emphasized enhanced eye tracking and imaging speed within its existing device ecosystem, while Sight Sciences' newly cleared OMNI Ultra system⁷ and BELKIN Vision's Eagle laser⁸ reflect the same broader wave of 510(k) clearances reshaping glaucoma diagnosis and treatment workflows this year.

References

1. Carl Zeiss Meditec AG. ZEISS CLINIC 360 receives FDA 510k clearance, amplifying patient care through simplified clinical insights. PR Newswire. Published August 19, 2026. Accessed August 20, 2026.

2. American Academy of Ophthalmology. EHRs: strategies for integrating diagnostic devices. EyeNet Magazine. Accessed August 20, 2026.

3. Ehrlich JR, Burke-Conte Z, Wittenborn JS, et al. Prevalence of glaucoma among US adults in 2022. JAMA Ophthalmol. Published online October 17, 2024. doi:10.1001/jamaophthalmol.2024.3884

4. BrightFocus Foundation. Glaucoma: facts & figures. BrightFocus Foundation. Accessed August 20, 2026.

5. Zeiss announces OCT technology enhancements to better support growing era of data-driven patient care. Ophthalmology Times. Accessed August 20, 2026.

6. Ophthalmology Times Staff. Heidelberg Engineering announces FDA clearance for new SPECTRALIS software release. Ophthalmology Times. Published June 11, 2026.

7. Stevenson S. FDA clears OMNI Ultra Surgical System, adding single-pass canaloplasty to implant-free MIGS platform. Ophthalmology Times. Published August 11, 2026.

8. Hutton D. FDA clears glaucoma laser device from BELKIN Vision. Ophthalmology Times. Published December 12, 2023.